President Donald Trump is slated to approve legislation this week that will give terminally-ill patients access to experimental drugs that haven’t yet been cleared by the FDA.
The “right-to-try” bill has sparked a great deal of controversy among policymakers and patient groups. While some, including the president, describe the effort as offering hope to patients with limited options, others argue that it undermines the FDA’s authority as the regulatory body charged with protecting patients.
Get the full story at our sister site, Drug Delivery Business News.
The post Report: Trump to sign controversial law granting patients access to experimental drugs appeared first on MassDevice.